EGFR and non-small cell lung carcinoma: In addition, compared with patients with 21-L858R, patients with 19-del who received TKIs had better overall survival, especially patients with advanced NSCLC.[22] In conclusion, different mutation statuses of EGFR can be used as prognostic factors for patients.